Lilly Sells Higher-Dose Zepbound Vials, Cuts Some Self-Pay Prices

Eli Lilly began offering higher-dose single‑dose vials of Zepbound (tirzepatide) in the United States on Jan. 3 and lowered the self-pay prices for several vial strengths sold through its LillyDirect portal, a company announcement said. The expanded vial lineup now includes 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg per 0.5 mL, and Lilly lists reduced monthly self-pay prices for direct purchases.

LillyDirect prices now show the recommended starting dose, 2.5 mg, at $299 per month, down from $349; the 5 mg dose at $399 per month, down from $499; and the higher doses, 7.5 mg, 10 mg, 12.5 mg and 15 mg, at $449 per month, down from $499. Lilly said the vial presentations are being offered at roughly a $150 discount relative to the multidose injector-pen formats, and characterized the steps as intended to improve availability and drive demand.

The price and formulation changes come as Lilly and other manufacturers agreed with the U.S. administration on a separate arrangement to make pen formulations of these weight‑loss drugs available to Medicare beneficiaries at an average price of about $245 per monthly dose, with a $50 monthly copay for enrollees. That agreement is expected to take effect in spring or summer 2026 and depends on pending regulatory actions for pen versions. The Medicare deal applies to the multidose pen presentations and does not change private insurance coverage or pricing for most commercially insured patients and the uninsured.

Public health advocates and clinicians say the changes are consequential because many patients seeking obesity treatment face affordability barriers that limit who can access clinically effective therapies. Lilly USA President Ilya Yuffa acknowledged those obstacles, saying many people who need obesity medication “still face cost and coverage barriers.” For patients paying out of pocket, the new vial pricing and expanded strengths could lower immediate costs and reduce the need to switch dosages when titrating treatment.

The vial format requires patients or caregivers to draw medication into a syringe and perform self-injection, a different workflow than the prefilled pen. Pharmacies and community clinicians will need to counsel patients on safe handling and dosing if more people choose vials for cost reasons. Lilly introduced single‑dose vials of Zepbound in August 2024 and has since expanded distribution channels; the company says direct-to-consumer purchases through LillyDirect now represent more than a third of new Zepbound prescriptions. A collaboration with a national retail pharmacy chain, announced last fall, made LillyDirect vials available for in-store pickup at hundreds of locations.

The company frames the price cuts and broader availability as steps to widen access, but systemic questions remain about equitable long-term access. Insurers determine coverage differently for vial and pen formulations, and out-of-pocket savings for self-pay customers do not address gaps in insurance formularies, prior authorization barriers, or disparities in care that disproportionately affect low-income and rural communities. As policy negotiations and regulatory reviews proceed, patients, providers and payers will be watching whether these commercial changes translate into sustained, affordable access across diverse populations.